125 related articles for article (PubMed ID: 36670542)
1. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract][Full Text] [Related]
2. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T
Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
6. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of APC and PTEN Alterations in Urachal Cancer.
Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T
Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865
[TBL] [Abstract][Full Text] [Related]
8. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
Collazo-Lorduy A; Castillo-Martin M; Wang L; Patel V; Iyer G; Jordan E; Al-Ahmadie H; Leonard I; Oh WK; Zhu J; McBride RB; Cordon-Cardo C; Solit DB; Sfakianos JP; Galsky MD
Eur Urol; 2016 Nov; 70(5):771-775. PubMed ID: 27178450
[TBL] [Abstract][Full Text] [Related]
9. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma.
Cornejo KM; Cosar EF; Paner GP; Yang P; Tomaszewicz K; Meng X; Mehta V; Sirintrapun SJ; Barkan GA; Hutchinson L
Int J Surg Pathol; 2020 Feb; 28(1):51-59. PubMed ID: 31496327
[No Abstract] [Full Text] [Related]
10. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
11. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing for identification of actionable gene mutations in intestinal-type sinonasal adenocarcinoma.
Sánchez-Fernández P; Riobello C; Costales M; Vivanco B; Cabal VN; García-Marín R; Suárez-Fernández L; López F; Cabanillas R; Hermsen MA; Llorente JL
Sci Rep; 2021 Jan; 11(1):2247. PubMed ID: 33500480
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
[TBL] [Abstract][Full Text] [Related]
15. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.
Szarvas T; Módos O; Niedworok C; Reis H; Szendröi A; Szász MA; Nyirády P
Urol Oncol; 2016 Sep; 34(9):388-98. PubMed ID: 27267737
[TBL] [Abstract][Full Text] [Related]
16. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Amin A; Murati-Amador B; Lombardo KA; Jackson CL; Grada Z; Palsgrove DN; Matoso A
Appl Immunohistochem Mol Morphol; 2020; 28(10):786-790. PubMed ID: 31876604
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.
Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R
Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Roy S; Pradhan D; Ernst WL; Mercurio S; Najjar Y; Parikh R; Parwani AV; Pai RK; Dhir R; Nikiforova MN
Mod Pathol; 2017 Aug; 30(8):1133-1143. PubMed ID: 28548125
[TBL] [Abstract][Full Text] [Related]
20. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
